What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue, stimulating the natural release of growth hormone from the pituitary gland. Unlike other growth hormone releasing peptides (GHRPs), Ipamorelin is highly selective and doesn't affect cortisol or ACTH levels, making it the "cleanest" GHRP available.
Selective Action
Ipamorelin selectively binds to ghrelin receptors in the pituitary gland, stimulating growth hormone release without affecting other hormones.
Clean Profile
Unlike GHRP-2 and GHRP-6, Ipamorelin doesn't increase cortisol or ACTH levels, providing growth hormone benefits without stress hormone elevation.
Research and Potential Benefits
Ipamorelin stimulates natural growth hormone release, leading to multiple physiological benefits without the side effects of synthetic growth hormone.
- ✓ Increased Muscle Mass: Promotes protein synthesis and muscle growth, leading to improved body composition.
- ✓ Fat Loss: Enhances lipolysis (fat breakdown) and improves metabolic rate.
- ✓ Improved Recovery: Accelerates healing and reduces recovery time from exercise and injury.
By restoring more youthful growth hormone levels, Ipamorelin provides significant anti-aging benefits that improve quality of life and longevity markers.
- ✓ Improved Sleep Quality: Enhances deep sleep phases and overall sleep architecture for better recovery.
- ✓ Enhanced Skin Health: Improves collagen production leading to increased skin elasticity and reduced wrinkles.
- ✓ Increased Energy: Boosts vitality and reduces fatigue through optimized cellular metabolism.
As a research peptide, Ipamorelin has demonstrated a favorable safety profile in clinical studies, but proper medical supervision is essential.
- ! Professional Guidance: Should only be used under the supervision of a qualified healthcare provider experienced with peptide therapy.
- ! Mild Side Effects: Generally well-tolerated; mild injection site reactions and temporary fatigue may occur initially.
- ! Contraindications: Not recommended for individuals with active cancer, severe kidney disease, or during pregnancy/breastfeeding.
References & Citations
- Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology.
- Johansen, P. B., et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research.
- Ankersen, M., et al. (1998). A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of Medicinal Chemistry.
Ask Dr. John About Ipamorelin
Get personalized clinical insights from Dr. Jobby John, PharmD, FACA. Ask specific questions about Ipamorelin and receive evidence-based answers from his extensive clinical experience.